Base de dados : MEDLINE
Pesquisa : D03.383.742.680.852.300.400 [Categoria DeCS]
Referências encontradas : 2463 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 247 ir para página                         

  1 / 2463 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28583799
[Au] Autor:Hasegawa Y; Takada T; Nakamura M; Yamana K
[Ad] Endereço:Department of Materials Science and Chemistry, University of Hyogo, 2167 Shosha, Himeji 671-2280, Japan.
[Ti] Título:Ferrocene conjugated oligonucleotide for electrochemical detection of DNA base mismatch.
[So] Source:Bioorg Med Chem Lett;27(15):3555-3557, 2017 08 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We describe the synthesis, binding, and electrochemical properties of ferrocene-conjugated oligonucleotides (Fc-oligos). The key step for the preparation of Fc-oligos contains the coupling of vinylferrocene to 5-iododeoxyuridine via Heck reaction. The Fc-conjugated deoxyuridine phosphoramidite was used in the Fc-oligonucleotide synthesis. We show that thiol-modified Fc-oligos deposited onto gold electrodes possess potential ability in electrochemical detection of DNA base mismatch.
[Mh] Termos MeSH primário: Pareamento Incorreto de Bases
DNA/genética
Desoxiuridina/análogos & derivados
Técnicas Eletroquímicas/métodos
Compostos Ferrosos/química
Oligonucleotídeos/química
[Mh] Termos MeSH secundário: Sequência de Bases
DNA/química
Eletrodos
Ouro/química
Idoxuridina/química
Metalocenos
Compostos de Vinila/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Ferrous Compounds); 0 (Metallocenes); 0 (Oligonucleotides); 0 (Vinyl Compounds); 1271-51-8 (vinylferrocene); 7440-57-5 (Gold); 9007-49-2 (DNA); LGP81V5245 (Idoxuridine); U96PKG90JQ (ferrocene); W78I7AY22C (Deoxyuridine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171125
[Lr] Data última revisão:
171125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE


  2 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28045991
[Au] Autor:Bayart E; Pouzoulet F; Calmels L; Dadoun J; Allot F; Plagnard J; Ravanat JL; Bridier A; Denozière M; Bourhis J; Deutsch E
[Ad] Endereço:INSERM U1030, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
[Ti] Título:Enhancement of IUdR Radiosensitization by Low-Energy Photons Results from Increased and Persistent DNA Damage.
[So] Source:PLoS One;12(1):e0168395, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Low-energy X-rays induce Auger cascades by photoelectric absorption in iodine present in the DNA of cells labeled with 5-iodo-2'-deoxyuridine (IUdR). This photoactivation therapy results in enhanced cellular sensitivity to radiation which reaches its maximum with 50 keV photons. Synchrotron core facilities are the only way to generate such monochromatic beams. However, these structures are not adapted for the routine treatment of patients. In this study, we generated two beams emitting photon energy means of 42 and 50 keV respectively, from a conventional 225 kV X-ray source. Viability assays performed after pre-exposure to 10 µM of IUdR for 48h suggest that complex lethal damage is generated after low energy photons irradiation compared to 137Cs irradiation (662KeV). To further decipher the molecular mechanisms leading to IUdR-mediated radiosensitization, we analyzed the content of DNA damage-induced foci in two glioblastoma cell lines and showed that the decrease in survival under these conditions was correlated with an increase in the content of DNA damage-induced foci in cell lines. Moreover, the follow-up of repair kinetics of the induced double-strand breaks showed the maximum delay in cells labeled with IUdR and exposed to X-ray irradiation. Thus, there appears to be a direct relationship between the reduction of radiation survival parameters and the production of DNA damage with impaired repair of these breaks. These results further support the clinical potential use of a halogenated pyrimidine analog combined with low-energy X-ray therapy.
[Mh] Termos MeSH primário: Sobrevivência Celular/efeitos dos fármacos
Dano ao DNA/efeitos dos fármacos
Relação Dose-Resposta à Radiação
Idoxuridina/farmacologia
Tolerância a Radiação/efeitos dos fármacos
Radiossensibilizantes/farmacologia
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Radioisótopos de Césio
Seres Humanos
Cinética
Fótons
Ratos
Síncrotrons
Proteína 1 de Ligação à Proteína Supressora de Tumor p53/metabolismo
Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cesium Radioisotopes); 0 (Radiation-Sensitizing Agents); 0 (TP53BP1 protein, human); 0 (Tumor Suppressor p53-Binding Protein 1); LGP81V5245 (Idoxuridine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170104
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0168395


  3 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27924163
[Au] Autor:Thisgaard H; Halle B; Aaberg-Jessen C; Olsen BB; Therkelsen AS; Dam JH; Langkjær N; Munthe S; Någren K; Høilund-Carlsen PF; Kristensen BW
[Ad] Endereço:PET & Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark;; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
[Ti] Título:Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery.
[So] Source:Theranostics;6(12):2278-2291, 2016.
[Is] ISSN:1838-7640
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Glioblastoma, the most common and malignant primary brain tumor, always recurs after standard treatment. Therefore, promising new therapeutic approaches are needed. Short-range Auger-electron-emitters carry the ability of causing highly damaging radiation effects in cells. The aim of this study was to test the effect of [ I]5-Iodo-2'-deoxyuridine ( I-UdR, a radioactive Auger-electron-emitting thymidine analogue) Auger-therapy on immature glioblastoma spheroid cultures and orthotopic xenografted glioblastoma-bearing rats, the latter by means of convection-enhanced delivery (CED). Moreover, we aimed to determine if the therapeutic effect could be enhanced when combining I-UdR therapy with the currently used first-line chemotherapeutic agent temozolomide. I-UdR significantly decreased glioblastoma cell viability and migration and the cell viability was further decreased by co-treatment with methotrexate and/or temozolomide. Intratumoral CED of methotrexate and I-UdR with and without concomitant systemic temozolomide chemotherapy significantly reduced the tumor burden in orthotopically xenografted glioblastoma-bearing nude rats. Thus, 100% (8/8) of the animals survived the entire observation period of 180 days when subjected to the combined Auger-chemotherapy while 57% (4/7) survived after the Auger-therapy alone. No animals (0/8) treated with temozolomide alone survived longer than 50 days. Blood samples and histology showed no signs of dose-limiting adverse effects. In conclusion, the multidrug approach consisting of CED of methotrexate and I-UdR with concomitant systemic temozolomide was safe and very effective leading to 100% survival in an orthotopic xenograft glioblastoma model. Therefore, this therapeutic strategy may be a promising option for future glioblastoma therapy.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Glioblastoma/radioterapia
Xenoenxertos
Idoxuridina/administração & dosagem
Radioterapia/métodos
[Mh] Termos MeSH secundário: Animais
Dacarbazina/administração & dosagem
Dacarbazina/análogos & derivados
Modelos Animais de Doenças
Quimioterapia Combinada
Metotrexato/administração & dosagem
Ratos Nus
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 7GR28W0FJI (Dacarbazine); LGP81V5245 (Idoxuridine); YF1K15M17Y (temozolomide); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161208
[St] Status:MEDLINE


  4 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27358459
[Au] Autor:Opendak M; Offit L; Monari P; Schoenfeld TJ; Sonti AN; Cameron HA; Gould E
[Ad] Endereço:Princeton Neuroscience Institute and.
[Ti] Título:Lasting Adaptations in Social Behavior Produced by Social Disruption and Inhibition of Adult Neurogenesis.
[So] Source:J Neurosci;36(26):7027-38, 2016 Jun 29.
[Is] ISSN:1529-2401
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Research on social instability has focused on its detrimental consequences, but most people are resilient and respond by invoking various coping strategies. To investigate cellular processes underlying such strategies, a dominance hierarchy of rats was formed and then destabilized. Regardless of social position, rats from disrupted hierarchies had fewer new neurons in the hippocampus compared with rats from control cages and those from stable hierarchies. Social disruption produced a preference for familiar over novel conspecifics, a change that did not involve global memory impairments or increased anxiety. Using the neuropeptide oxytocin as a tool to increase neurogenesis in the hippocampus of disrupted rats restored preference for novel conspecifics to predisruption levels. Conversely, reducing the number of new neurons by limited inhibition of adult neurogenesis in naive transgenic GFAP-thymidine kinase rats resulted in social behavior similar to disrupted rats. Together, these results provide novel mechanistic evidence that social disruption shapes behavior in a potentially adaptive way, possibly by reducing adult neurogenesis in the hippocampus. SIGNIFICANCE STATEMENT: To investigate cellular processes underlying adaptation to social instability, a dominance hierarchy of rats was formed and then destabilized. Regardless of social position, rats from disrupted hierarchies had fewer new neurons in the hippocampus compared with rats from control cages and those from stable hierarchies. Unexpectedly, these changes were accompanied by changes in social strategies without evidence of impairments in cognition or anxiety regulation. Restoring adult neurogenesis in disrupted rats using oxytocin and conditionally suppressing the production of new neurons in socially naive GFAP-thymidine kinase rats showed that loss of 6-week-old neurons may be responsible for adaptive changes in social behavior.
[Mh] Termos MeSH primário: Adaptação Psicológica/fisiologia
Hipocampo/citologia
Neurogênese/fisiologia
Comportamento Social
[Mh] Termos MeSH secundário: Animais
Ansiedade/metabolismo
Ansiedade/patologia
Modelos Animais de Doenças
Proteína Glial Fibrilar Ácida/genética
Proteína Glial Fibrilar Ácida/metabolismo
Hidrocortisona/sangue
Idoxuridina/farmacologia
Masculino
Neurogênese/efeitos dos fármacos
Inibidores da Síntese de Ácido Nucleico/farmacologia
Ocitocina/farmacologia
Fosfopiruvato Hidratase/metabolismo
Ratos
Ratos Long-Evans
Ratos Sprague-Dawley
Ratos Transgênicos
Testosterona/sangue
Vocalização Animal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glial Fibrillary Acidic Protein); 0 (Nucleic Acid Synthesis Inhibitors); 3XMK78S47O (Testosterone); 50-56-6 (Oxytocin); EC 4.2.1.11 (Phosphopyruvate Hydratase); LGP81V5245 (Idoxuridine); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170909
[Lr] Data última revisão:
170909
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160701
[St] Status:MEDLINE
[do] DOI:10.1523/JNEUROSCI.4435-15.2016


  5 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27214141
[Au] Autor:El Aissi R; Miladi I; Chezal JM; Chavignon O; Miot-Noirault E; Moreau E
[Ad] Endereço:INSERM - Université d'Auvergne, UMR 990, IMTV, BP 184, F-63005 Clermont-Ferrand Cedex, France; Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63005 Clermont-Ferrand Cedex, France.
[Ti] Título:Melanoma-targeted delivery system (part 2): Synthesis, radioiodination and biological evaluation in B16F0 bearing mice.
[So] Source:Eur J Med Chem;120:304-12, 2016 Sep 14.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Here we report the synthesis and radiolabelling with iodine-125 of a melanoma-selective prodrug (17a*) and its parent drug IUdR. The in vivo and ex vivo biodistributions of [(125)I](17a*) and [(125)I]IUdR were evaluated in a model of melanoma B16F0-bearing mice. The pharmacokinetic profile of [(125)I](17a*) suggests rapid release of the active drug [(125)I]IUdR after i.v. administration of [(125)I](17a*). Preliminary metabolism studies in dedicated compartments (i.e. blood, urine and tumour) yielded results consistent with this hypothesis.
[Mh] Termos MeSH primário: Melanoma/tratamento farmacológico
Pró-Fármacos/farmacocinética
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Idoxuridina/farmacocinética
Radioisótopos do Iodo/administração & dosagem
Radioisótopos do Iodo/farmacocinética
Camundongos
Pró-Fármacos/administração & dosagem
Compostos Radiofarmacêuticos/administração & dosagem
Compostos Radiofarmacêuticos/farmacocinética
Distribuição Tecidual
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Prodrugs); 0 (Radiopharmaceuticals); LGP81V5245 (Idoxuridine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170213
[Lr] Data última revisão:
170213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160524
[St] Status:MEDLINE


  6 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26748400
[Au] Autor:Khoei S; Shoja M; Mostaar A; Faeghi F
[Ad] Endereço:Medical Physics Department, School of Medicine, Iran University of Medical Sciences, Tehran 1449614525, Iran Razi Drug Research Centre, Iran University of Medical Sciences, Tehran 1449614525, Iran Khoei.s@iums.ac.ir.
[Ti] Título:Effects of resveratrol and methoxyamine on the radiosensitivity of iododeoxyuridine in U87MG glioblastoma cell line.
[So] Source:Exp Biol Med (Maywood);241(11):1229-36, 2016 Jun.
[Is] ISSN:1535-3699
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to evaluate the combination effect of resveratrol and methoxyamine on radiosensitivity of iododeoxyuridine in spheroid culture of U87MG glioblastoma cell line using colony formation and alkaline comet assays. Spheroids on day-20 with 350 µm diameters were treated with 20 µM resveratrol and/or 6 mM methoxyamine and/or 1 µM iododeoxyuridine for one volume doubling time (67 h), and then irradiated with 2 Gy gamma-radiation ((60)Co) in different groups. After treatment, viability of the cells, colony forming ability and DNA damages were obtained by blue dye exclusion, colony formation and alkaline comet assay, respectively. Our results showed that methoxyamine and resveratrol could significantly reduce colony number and induce the DNA damages of glioblastoma spheroid cells treated with iododeoxyuridine in combination with gamma-rays. Therefore, methoxyamine as base excision repair inhibitor and resveratrol as hypoxia inducible factor 1-alpha inhibitor in combination with iododeoxyuridine as radiosensitizer enhanced the radiosensitization of glioblastoma spheroid cells.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Hidroxilaminas/farmacologia
Idoxuridina/farmacologia
Neuroglia/efeitos dos fármacos
Neuroglia/efeitos da radiação
Radiossensibilizantes/farmacologia
Estilbenos/farmacologia
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos da radiação
Ensaio de Unidades Formadoras de Colônias
Ensaio Cometa
Raios gama
Seres Humanos
Neuroglia/fisiologia
Tolerância a Radiação/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hydroxylamines); 0 (Radiation-Sensitizing Agents); 0 (Stilbenes); 9TZH4WY30J (methoxyamine); LGP81V5245 (Idoxuridine); Q369O8926L (resveratrol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160110
[St] Status:MEDLINE
[do] DOI:10.1177/1535370215622583


  7 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26210505
[Au] Autor:El Aissi R; Chezal JM; Tarrit S; Chavignon O; Moreau E
[Ad] Endereço:INSERM - Université d'Auvergne, UMR 990, IMTV, BP 184, F-63005 Clermont-Ferrand Cedex, France; Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63005 Clermont-Ferrand Cedex, France.
[Ti] Título:Melanoma-targeted delivery system (part 1): design, synthesis and evaluation of releasable disulfide drug by glutathione.
[So] Source:Eur J Med Chem;101:668-80, 2015 Aug 28.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Here we describe the design and synthesis of a prodrug developed for pigmented melanoma therapy, consisting of a Melanin-Targeting Probe (MTP) conjugated to 5-iodo-2'-deoxyuridine (IUdR) with a reduction-sensitive pre-determined breaking point. Compared with the non-cleavable conjugate (17b), prodrug (17a) bearing a self-immolative disulfide linker achieved complete release of IUdR within 20 min in the presence of reducing agents such as DTT or glutathione. Analytical results also showed that prodrug (17a) was more sensitive than parent non-cleavable conjugate (17b) for a concentration range of glutathione similar to that found in the intracellular compartment of tumours.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Dissulfetos/farmacologia
Sistemas de Liberação de Medicamentos
Desenho de Drogas
Liberação Controlada de Fármacos
Glutationa/farmacologia
Melanoma/tratamento farmacológico
Melanoma/metabolismo
Pró-Fármacos/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos/síntese química
Antineoplásicos/química
Dissulfetos/síntese química
Dissulfetos/química
Glutationa/síntese química
Glutationa/química
Seres Humanos
Idoxuridina/química
Estrutura Molecular
Pró-Fármacos/síntese química
Pró-Fármacos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Disulfides); 0 (Prodrugs); GAN16C9B8O (Glutathione); LGP81V5245 (Idoxuridine)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150818
[Lr] Data última revisão:
150818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150727
[St] Status:MEDLINE


  8 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26161977
[Au] Autor:Ligasová A; Liboska R; Rosenberg I; Koberna K
[Ad] Endereço:Institute of Molecular and Translational Medicine, Faculty of Medicine, Palacký University, Olomouc, Czech Republic.
[Ti] Título:The Fingerprint of Anti-Bromodeoxyuridine Antibodies and Its Use for the Assessment of Their Affinity to 5-Bromo-2'-Deoxyuridine in Cellular DNA under Various Conditions.
[So] Source:PLoS One;10(7):e0132393, 2015.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have developed a simple system for the analysis of the affinity of anti-bromodeoxyuridine antibodies. The system is based on the anchored oligonucleotides containing 5-bromo-2'-deoxyuridine (BrdU) at three different positions. It allows a reliable estimation of the reactivity of particular clones of monoclonal anti-bromodeoxyuridine antibodies with BrdU in fixed and permeabilized cells. Using oligonucleotide probes and four different protocols for the detection of BrdU incorporated in cellular DNA, we identified two antibody clones that evinced sufficient reactivity to BrdU in all the tested protocols. One of these clones exhibited higher reactivity to 5-iodo-2'-deoxyuridine (IdU) than to BrdU. It allowed us to increase the sensitivity of the used protocols without a negative effect on the cell physiology as the cytotoxicity of IdU was comparable with BrdU and negligible when compared to 5-ethynyl-2'-deoxyuridine. The combination of IdU and the improved protocol for oxidative degradation of DNA provided a sensitive and reliable approach for the situations when the low degradation of DNA and high BrdU signal is a priority.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/metabolismo
Bromodesoxiuridina/metabolismo
DNA/metabolismo
Mapeamento de Peptídeos
[Mh] Termos MeSH secundário: Células Clonais
Células HCT116
Células HeLa
Seres Humanos
Idoxuridina/análogos & derivados
Idoxuridina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 14259-58-6 (5'-deoxy-5'-iodouridine); 9007-49-2 (DNA); G34N38R2N1 (Bromodeoxyuridine); LGP81V5245 (Idoxuridine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150711
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0132393


  9 / 2463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25928630
[Au] Autor:Balderson DE; Cai G; Fries MA; Kleinman DM; McLaughlin MM; Trivedi TM; Wurzelmann JI; Young SB
[Ad] Endereço:GlaxoSmithKline, Five Moore Drive, Research Triangle Park, Durham, NC, 27709, USA. diane.e.balderson@gsk.com.
[Ti] Título:A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatment.
[So] Source:BMC Ophthalmol;15:42, 2015 Apr 17.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This objective of the review and analysis is to demonstrate that acyclovir (ACV) 3% ophthalmic ointment is superior to idoxuridine (IDU) in treating herpetic keratitis (HK) presenting as dendritic and geographic ulcer sub-types. DATA SOURCES: Publications in human subjects were identified by searching the Ovid MEDLINE database through April 2011, combining medical subject headings (MESH) "Keratitis, Herpetic/" AND "Acyclovir/" limiting by the key words "topical" OR "ointment" and also restricted to MESH "Administration, Topical/" OR "Ointments/". The results were cross checked with the references used in the Cochrane Database Syst Rev. 1:1-134, 2009 and GlaxoSmithKline clinical documents related to acyclovir. STUDY SELECTION: Randomized, double-masked studies in subjects diagnosed with HK with head to head comparator arms of ACV ophthalmic ointment and topical IDU that had actual or calculable healing rates at Day seven. DATA EXTRACTION: Data independently extracted from identified articles by two authors of this manuscript. DATA SYNTHESIS: Data from seven randomized, controlled trials (RCT) evaluating 432 subjects that met inclusion criteria (214 were treated with ACV and 218 were treated with IDU) and had Day seven healing rates calculable. All sub-classified lesions were identified as either dendritic ulcers (n = 185) or geographic ulcers (n = 35). The Cochran-Mantel-Haenszel (CMH) method in Biometrics 10:417-51, 1954 and JNCI 22:719-48, 1959, controlling for study, was performed as the primary analysis using SAS v9. Homogeneity was assessed using Breslow-Day-Tarone (BDT) test in IARC 1:1-32, 1980 and Biometrika 72:91-5, 1985. The analysis was performed with outliers removed to assess their impact. RESULTS: ACV showed statistically significant greater odds of healing HK at Day seven in all subjects (Odds Ratio 3.95, 95% CI2.60, 6.00, p < 0.0001), in dendritic ulcers (Odds Ratio 4.22, 95% CI: 2.14, 8.32; p < 0.0001) and geographic ulcers (Odds Ratio 5.31, 95% CI: 1.09, 25.93; p = 0.0244). CONCLUSION: ACV 3% ophthalmic ointment is a valuable intervention for dendritic and geographic corneal ulcers. ACV and IDU were generally well tolerated in the studies reviewed.
[Mh] Termos MeSH primário: Aciclovir/administração & dosagem
Idoxuridina/administração & dosagem
Ceratite Herpética/tratamento farmacológico
[Mh] Termos MeSH secundário: Antivirais/administração & dosagem
Seguimentos
Seres Humanos
Pomadas
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Ointments); LGP81V5245 (Idoxuridine); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150501
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-015-0022-2


  10 / 2463 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25754887
[Au] Autor:Kore AR; Yang B; Srinivasan B
[Ad] Endereço:Life Sciences Solutions Group, Thermo Fisher Scientific, Austin, Texas.
[Ti] Título:Fluorous-assisted synthesis of (E)-5-[3-aminoallyl]-uridine-5'-O-triphosphate.
[So] Source:Curr Protoc Nucleic Acid Chem;60:1.33.1-10, 2015 Mar 09.
[Is] ISSN:1934-9289
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An efficient, reliable method for the chemical synthesis of (E)-5-[3-aminoallyl]-uridine-5'-O-triphosphate (AA-UTP), starting from 5-iodouridine, is described. This new strategy features the involvement of one-pot triphosphate formation and fluorous solid-phase extraction (F-SPE). The one-pot synthesis involves the mono phosphorylation of fluorous-tagged uridine, followed by the reaction with pyrophosphate to afford the fluorous-tagged AA-UTP. The F-SPE is achieved by installing a fluorous-tag onto the uridine prior to triphosphate formation, purification via F-SPE, and cleavage of the fluorous-tag. It is worth mentioning that this protocol produces AA-UTP in high yield and purity using one simple F-SPE; no conventional column chromatography is involved.
[Mh] Termos MeSH primário: Idoxuridina/análogos & derivados
Extração em Fase Sólida/métodos
Uridina Trifosfato/síntese química
[Mh] Termos MeSH secundário: Cromatografia
Idoxuridina/síntese química
Idoxuridina/química
Estrutura Molecular
Técnicas de Síntese em Fase Sólida
Uridina Trifosfato/análogos & derivados
Uridina Trifosfato/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1024-99-3 (5-iodouridine); LGP81V5245 (Idoxuridine); UT0S826Z60 (Uridine Triphosphate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:161021
[Lr] Data última revisão:
161021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150311
[St] Status:MEDLINE
[do] DOI:10.1002/0471142700.nc0133s60



página 1 de 247 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde